Clinical trials: New Onset Diabetes After Transplant
Maintenance Liver Transplant Patients With New Onset Diabetes
Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant
The trial is conducted in patients who have received a liver transplant, were prescribed tacrolimus to prevent organ rejection and developed diabetes from 3 month post-transplantation onwards.
- Trial name
- NCT00171717
- Testing
- Cyclosporine - cyclosporine microemulsion
- Volunteers
- 39 people
- Sponsor
- Novartis
Kidney Transplant
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients
The purpose of this study is to evaluate the impact of tacrolimus and cyclosporine microemulsion on glucose metabolism in kidney transplant recipients and the efficacy and safety in preventing organ rejection
- Trial name
- NCT00171496
- Testing
- Cyclosporine microemulsion, Tacrolimus
- Volunteers
- 693 people
- Sponsor
- Novartis
de Novo Kidney Transplantation
Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation
To investigate the efficacy, safety, and drug compliance of Advagraf® (Extended Release Tacrolimus) by comparing the Advagraf® + steroid + Mycophenolate Mofetil combined therapy and the Prograf® + steroid + Mycophenolate Mofetil…
- Trial name
- AdProCISE (NCT01742624)
- Testing
- Advagraf, Prograf, Corticosteroid
- Where
- 3 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Korea, Inc.